EpiCast Report: Epilepsy - Epidemiology Forecast to 2026
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
EpiCast Report: Epilepsy - Epidemiology Forecast to 2026
Summary
Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain. It is one of the most common neurological conditions globally. Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered at least one epileptic seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis. Although there is no cure for epilepsy, the majority of patients can successfully stop or reduce their number of seizures with anti-epileptic drug (AED) treatment. However, there are some cases where seizures persist even with AED treatment.
To forecast the lifetime and active diagnosed cases of epilepsy in the 7MM, GlobalData epidemiologists utilized country-specific studies published in peer reviewed journals and by the WHO from at least 10 years of historical data. Prevalent cases of epilepsy are segmented by active and lifetime prevalence. Additional segmentation of prevalence was provided for seizure type, age, and sex to provide the most refined and granular forecast results. The forecast methodology for this forecast was kept consistent across all seven markets to allow for a meaningful global comparison.
In the 7MM, the lifetime diagnosed prevalent cases of epilepsy are expected to increase from 10,985,423 cases in 2016 to 11,510,475 cases in 2026, at an Annual Growth Rate (AGR) of 0.48% per year. In 2016, there were 5,661,175 active diagnosed prevalent cases of epilepsy in the 7MM, which is expected to increase to 6,027,806 cases by 2026, at an AGR of 0.65%.
Scope
- The Epilepsy EpiCast Report provides an overview of the risk factors and global trends of epilepsy in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the lifetime and active diagnosed prevalent cases of epilepsy in these markets from 2016-2026. The lifetime and active diagnosed prevalent cases are segmented by sex and age (ranging from age 0 to ages 80 years and older). The active diagnosed prevalent cases are further segmented by seizure type (generalized, focal, unclassified/unknown) and drug resistance.
- The epilepsy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Epilepsy EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global epilepsy market.
- Quantify patient populations in the global epilepsy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for epilepsy therapeutics in each of the markets covered.
- Understand seizure type and drug resistance in active diagnosed prevalent cases of epilepsy.
Summary
Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain. It is one of the most common neurological conditions globally. Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered at least one epileptic seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis. Although there is no cure for epilepsy, the majority of patients can successfully stop or reduce their number of seizures with anti-epileptic drug (AED) treatment. However, there are some cases where seizures persist even with AED treatment.
To forecast the lifetime and active diagnosed cases of epilepsy in the 7MM, GlobalData epidemiologists utilized country-specific studies published in peer reviewed journals and by the WHO from at least 10 years of historical data. Prevalent cases of epilepsy are segmented by active and lifetime prevalence. Additional segmentation of prevalence was provided for seizure type, age, and sex to provide the most refined and granular forecast results. The forecast methodology for this forecast was kept consistent across all seven markets to allow for a meaningful global comparison.
In the 7MM, the lifetime diagnosed prevalent cases of epilepsy are expected to increase from 10,985,423 cases in 2016 to 11,510,475 cases in 2026, at an Annual Growth Rate (AGR) of 0.48% per year. In 2016, there were 5,661,175 active diagnosed prevalent cases of epilepsy in the 7MM, which is expected to increase to 6,027,806 cases by 2026, at an AGR of 0.65%.
Scope
- The Epilepsy EpiCast Report provides an overview of the risk factors and global trends of epilepsy in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of the lifetime and active diagnosed prevalent cases of epilepsy in these markets from 2016-2026. The lifetime and active diagnosed prevalent cases are segmented by sex and age (ranging from age 0 to ages 80 years and older). The active diagnosed prevalent cases are further segmented by seizure type (generalized, focal, unclassified/unknown) and drug resistance.
- The epilepsy epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Epilepsy EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global epilepsy market.
- Quantify patient populations in the global epilepsy market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for epilepsy therapeutics in each of the markets covered.
- Understand seizure type and drug resistance in active diagnosed prevalent cases of epilepsy.
TABLE OF CONTENTS
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Epilepsy: Executive Summary 4
2.1 Related Reports 7
2.2 Upcoming Related Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 9
3.3.1 US 11
3.3.2 5EU 12
3.3.3 Japan 12
3.4 Forecast Methodology 13
3.4.1 Sources 14
3.4.2 Forecast Assumptions and Methods 18
3.5 Epidemiological Forecast for Epilepsy (2016-2026) 28
3.5.1 Lifetime Diagnosed Prevalent Cases of Epilepsy 28
3.5.2 Active Diagnosed Prevalent Cases of Epilepsy 29
3.5.3 Age-Specific Active Diagnosed Prevalent Cases of Epilepsy 30
3.5.4 Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy 31
3.5.5 Active Diagnosed Prevalent Cases by Seizure Type 32
3.5.6 Drug Resistant Active Diagnosed Prevalent Cases 33
3.6 Discussion 34
3.6.1 Epidemiological Forecast Insight 34
3.6.2 Limitations of the Analysis 36
3.6.3 Strengths of the Analysis 36
4 Appendix 37
4.1 Bibliography 37
4.2 Primary Research - Prescriber Survey 42
4.3 About the Authors 42
4.3.1 Epidemiologist 42
4.3.2 Reviewers 42
4.3.3 Global Director of Therapy Analysis and Epidemiology 43
4.3.4 Global Head and EVP of Healthcare Operations and Strategy 44
4.4 About GlobalData 45
4.5 Contact Us 45
4.6 Disclaimer 45
Table 1: Risk Factors and Comorbidities for Epilepsy 9
Table 2: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026. 29
Table 3: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026 30
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 42
Figure 1: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026 5
Figure 2: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026 6
Figure 3: 7MM Age-Standardized Lifetime Diagnosed Prevalence, Men, Women, All Ages, 2016 (%) 10
Figure 4: 7MM Age-standardized Active Diagnosed Prevalence, Men, Women, All Ages, 2016 (%) 11
Figure 5: The Sources Used to Calculate the Lifetime Diagnosed Prevalence of Epilepsy 14
Figure 6: The Sources Used and Not Used in the Forecast for the Active Diagnosed Prevalence 15
Figure 7: The Sources Used and Not Used in the Forecast for the Seizure Type Distribution of Active Diagnosed Prevalent Cases 17
Figure 8: The Sources Used in the Forecast for the Drug Resistant Active Diagnosed Prevalent Cases 18
Figure 9: 7MM, Age-Specific Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, 2016 31
Figure 10: 7MM Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy, All Ages, 2016. 32
Figure 11: 7MM, Active Diagnosed Prevalent Cases of Epilepsy by Seizure Type, Men and Women, All Ages, 2016 33
Figure 12: 7MM, Active Diagnosed Prevalent Cases by Response to AED Treatment, Men and Women, All Ages, 2016. 34
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Epilepsy: Executive Summary 4
2.1 Related Reports 7
2.2 Upcoming Related Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 9
3.3.1 US 11
3.3.2 5EU 12
3.3.3 Japan 12
3.4 Forecast Methodology 13
3.4.1 Sources 14
3.4.2 Forecast Assumptions and Methods 18
3.5 Epidemiological Forecast for Epilepsy (2016-2026) 28
3.5.1 Lifetime Diagnosed Prevalent Cases of Epilepsy 28
3.5.2 Active Diagnosed Prevalent Cases of Epilepsy 29
3.5.3 Age-Specific Active Diagnosed Prevalent Cases of Epilepsy 30
3.5.4 Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy 31
3.5.5 Active Diagnosed Prevalent Cases by Seizure Type 32
3.5.6 Drug Resistant Active Diagnosed Prevalent Cases 33
3.6 Discussion 34
3.6.1 Epidemiological Forecast Insight 34
3.6.2 Limitations of the Analysis 36
3.6.3 Strengths of the Analysis 36
4 Appendix 37
4.1 Bibliography 37
4.2 Primary Research - Prescriber Survey 42
4.3 About the Authors 42
4.3.1 Epidemiologist 42
4.3.2 Reviewers 42
4.3.3 Global Director of Therapy Analysis and Epidemiology 43
4.3.4 Global Head and EVP of Healthcare Operations and Strategy 44
4.4 About GlobalData 45
4.5 Contact Us 45
4.6 Disclaimer 45
List Of Tables
Table 1: Risk Factors and Comorbidities for Epilepsy 9
Table 2: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026. 29
Table 3: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, Select Years 2016-2026 30
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 42
List Of Figures
Figure 1: 7MM, Lifetime Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026 5
Figure 2: 7MM, Active Diagnosed Prevalent Cases of Epilepsy, Both Sexes, All Ages, 2016 and 2026 6
Figure 3: 7MM Age-Standardized Lifetime Diagnosed Prevalence, Men, Women, All Ages, 2016 (%) 10
Figure 4: 7MM Age-standardized Active Diagnosed Prevalence, Men, Women, All Ages, 2016 (%) 11
Figure 5: The Sources Used to Calculate the Lifetime Diagnosed Prevalence of Epilepsy 14
Figure 6: The Sources Used and Not Used in the Forecast for the Active Diagnosed Prevalence 15
Figure 7: The Sources Used and Not Used in the Forecast for the Seizure Type Distribution of Active Diagnosed Prevalent Cases 17
Figure 8: The Sources Used in the Forecast for the Drug Resistant Active Diagnosed Prevalent Cases 18
Figure 9: 7MM, Age-Specific Active Diagnosed Prevalent Cases of Epilepsy, Men and Women, All Ages, 2016 31
Figure 10: 7MM Sex-Specific Active Diagnosed Prevalent Cases of Epilepsy, All Ages, 2016. 32
Figure 11: 7MM, Active Diagnosed Prevalent Cases of Epilepsy by Seizure Type, Men and Women, All Ages, 2016 33
Figure 12: 7MM, Active Diagnosed Prevalent Cases by Response to AED Treatment, Men and Women, All Ages, 2016. 34
RELATED REPORTS
EpiCast Report: Glaucoma - Epidemiology Forecast to 2026
EpiCast Report: Glaucoma - Epidemiology Forecast to 2026Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eyes optic nerve, resulting in progressive, irreversible vision loss.
View ReportEpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026
EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the
View ReportEpiCast Report: Glaucoma - Epidemiology Forecast to 2026
EpiCast Report: Glaucoma - Epidemiology Forecast to 2026Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eyes optic nerve, resulting in progressive, irreversible vision loss.
View ReportEpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026
EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
